Urologic Oncology letter disputes calendar-time bias claim in GLP-1 bladder cancer study

The wire

1. 01Kohler, Rodler and colleagues published a response to a critique alleging calendar-time bias in their TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival.
2. 02Clinicians citing real-world database claims about GLP-1 drugs and cancer outcomes should note the methodological dispute behind them.
3. 03Only the correspondence title is available; the authors' specific rebuttal and any reanalysis are not described.

From the source

Response to "Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival"

Urologic oncology · 2026 Oct 13 · Kohler J, Rodler S et al.